Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Anterior Uveitis

Anterior uveitis is the most common form of uveitis [S5], with a reported annual incidence of 12/100,000 population (23/100,000 in Finland) [S1]. It is often self-limiting but can lead to posterior synechiae, cataract, glaucoma and chronic uveitis [S1]. The clinical task is to characterise it, exclude infection and masquerade, and escalate treatment when topical steroids are not enough [S5] [S10].

Key points - Before labelling uveitis as anterior and non-infectious, examine the posterior segment and rule out masquerade syndromes; the priority of the work-up is to rule out infection [S5]. - Raised intraocular pressure (IOP), corneal involvement or iris atrophy should raise suspicion of viral anterior uveitis [S6] [S7]. - HLA-B27 links anterior uveitis with spondyloarthritis: about 50% of patients with anterior uveitis have spondyloarthritis [S2]. - Most anatomically isolated anterior uveitis resolves with topical corticosteroids; some patients need systemic immunomodulatory therapy (IMT) [S10]. - Investigations should be targeted by clinical findings and regional epidemiology, not ordered as a blanket panel [S10].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• High IOP with anterior uveitis. Suggests a viral cause (herpes simplex, varicella-zoster, cytomegalovirus or rubella) [S6] [S7]. Posner-Schlossman syndrome (mainly cytomegalovirus) can present with extremely high IOP and minimal cells [S6] and can result in chronic secondary glaucoma [S3].
• Possible infection. Ruling out infection is the priority of the work-up [S5]; untreated cytomegalovirus anterior uveitis may progress to glaucoma [S9].
• Posterior segment involvement or atypical features. Examine the posterior segment and consider masquerade syndromes before treating as isolated anterior uveitis [S5].
• Poor response, steroid dependence or steroid side effects. These are triggers to consider systemic IMT [S10].
• A child with chronic anterior uveitis. Children with juvenile idiopathic arthritis-associated uveitis or idiopathic chronic anterior uveitis are managed under dedicated paediatric recommendations [S8].

Recognise it

• Laterality and granulomatous features. After ruling out masquerade, clinical characterisation (unilateral vs bilateral, granulomatous vs non-granulomatous) is the main step of etiologic diagnosis [S5].
• HLA-B27 / spondyloarthritis pattern. Typically unilateral, with a marked tendency to recur, often alternating between eyes, and a good prognosis in most cases [S2]. Anterior uveitis is reported in at least 30% of people with spondyloarthritis, with a peak of 33.4% in ankylosing spondylitis; in inflammatory bowel disease-associated spondyloarthritis about 25%, and in psoriatic arthritis 2%-25% [S2]. Uveitis may precede the joint disease [S2].
• Viral patterns (overlap is considerable) [S6]:
• Granulomatous clusters of small and medium keratic precipitates in Arlt's triangle, with or without corneal scars: herpes simplex or varicella-zoster [S6].
• Few medium keratic precipitates, minimal cells and extremely high IOP (Posner-Schlossman syndrome): mainly cytomegalovirus [S6]. Attacks are recurrent, unilateral and non-granulomatous, mostly in middle-aged men [S3].
• Fuchs uveitis syndrome: fine stellate keratic precipitates across the endothelium, diffuse iris stromal atrophy and no posterior synechiae; mainly rubella or cytomegalovirus [S6].
• Cytomegalovirus anterior uveitis is highly prevalent in Asia and more common in men [S9]; it predominantly affects Asian males in the fifth to seventh decade, sometimes with coin-shaped keratic precipitates or nodular endothelial lesions [S6].
• Tubulointerstitial nephritis and uveitis (TINU) is under-recognised and occurs at all ages, not only in children [S4].

Confirm it

• Targeted routine tests. Chest radiography and serology for syphilis, HLA-B27 and angiotensin-converting enzyme are appropriate in severe, bilateral, recurrent or chronic anterior uveitis [S10].
• Further tests should follow clinical findings and regional epidemiology; untargeted investigations are of limited use and costly [S10].
• Aqueous humour analysis. Quantitative polymerase chain reaction (PCR) or the Goldmann-Witmer coefficient on aqueous helps confirm a viral cause and its severity, which guides treatment [S6] [S7].
• TINU. Urinary β2-microglobulin is a sensitive and specific screening test; the role of kidney biopsy in separating TINU from sarcoidosis is evolving [S4].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Anterior uveitis needs a full eye examination, including the posterior segment, to rule out infection and masquerade before treatment [S5]; refer rather than treat empirically (timing in the table below).
• People with ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease are at higher risk of anterior uveitis [S2]; recurrent episodes need an eye clinic each time [S2].

Tier B (general eye clinic)

1. Characterise and exclude infection before steroids: laterality, granulomatous features, IOP, corneal signs and the posterior segment [S5] [S6].
2. Topical treatment. Most isolated anterior uveitis resolves with topical corticosteroids [S10]. A BMJ Clinical Evidence systematic review graded the evidence on corticosteroid, mydriatic and non-steroidal anti-inflammatory eye drops for acute anterior uveitis, but its abstract does not report the effect sizes [S1]. Dosing is not covered by these abstracts: follow local formularies.
3. Targeted tests for severe, bilateral, recurrent or chronic disease [S10].
4. Comanage conventional IMT (methotrexate, azathioprine, mycophenolate mofetil) with rheumatology when steroids fail, cause limiting side effects, are needed at high doses, or there is systemic inflammatory disease [S10].

Tier C (specialist centre)

• Viral anterior uveitis. Confirm by aqueous PCR or Goldmann-Witmer coefficient [S6] [S7]. For cytomegalovirus anterior uveitis, early antiviral treatment reduces the risk of needing glaucoma surgery; oral valganciclovir and topical ganciclovir both produced positive outcomes, and an extended course could prevent relapse but should be limited to 6 months to limit resistance and side effects (narrative review) [S9]. Posner-Schlossman syndrome is often managed topically, but systemic therapy or surgery may be required [S3].
• Escalation. When quiescence is not reached on maximally tolerated antimetabolites, refer to a uveitis specialist for IMT escalation [S10]. Biologics have changed management of HLA-B27 and juvenile idiopathic arthritis-associated anterior uveitis [S5]; anti-tumour necrosis factor-α treatment of spondyloarthritis reduced anterior uveitis occurrence and flares [S2].
• Children with chronic anterior uveitis. Follow the 2023 MIWGUC update of the SHARE recommendations (14 consensus recommendations, >90% agreement) [S8].
• TINU. Management now includes systemic anti-inflammatory treatment for significant ocular and renal disease [S4].

Refer when

Pitfalls

• Treating every anterior uveitis with steroids without excluding infection [S5].
• Missing a viral cause in hypertensive uveitis; cytomegalovirus anterior uveitis may progress to glaucoma without prompt treatment [S9].
• Ordering broad, untargeted test panels [S10].
• Not asking about back, joint, skin and bowel symptoms in recurrent unilateral disease [S2].
• Overlooking TINU in adults [S4].

Evidence notes

• Thin evidence. The search sheet returned mostly Behçet's syndrome reviews; apart from one 2010 systematic review [S1] and a paediatric consensus [S8], the sources here are narrative reviews (expert opinion level).
• The only systematic review of eye drops [S1] is from 2010 and its abstract does not give effect sizes or a conclusion on which drop works best.
• The 6-month limit on cytomegalovirus antiviral courses is a review recommendation, not trial evidence [S9].
• Referral timing depends on local factors [S10]; the timings in "Refer when" need Editor-in-Chief confirmation.
• Not covered by these sources: symptoms at presentation, specific steroid and cycloplegic regimens and doses, steroid-induced IOP rise, management of herpetic anterior uveitis, and cost or access in low-resource settings.

Related articles

• Biologics and Immunosuppression for Non-infectious Uveitis
• Juvenile Idiopathic Arthritis-associated Uveitis
• Topical and periocular corticosteroids: benefits and risks

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.